Clinical Trials Logo

Polyradiculoneuropathy clinical trials

View clinical trials related to Polyradiculoneuropathy.

Filter by:

NCT ID: NCT01017159 Completed - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether subcutaneous immunoglobulin given in small doses, is effective in maintaining the force, in patients with chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo (saline infusions), and intravenous immunoglobulin.

NCT ID: NCT00305266 Completed - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Study of CIDP Patients During IVIG Treatment

Start date: August 2005
Phase: N/A
Study type: Observational

The aim of this study is to quantify the effect of IVIG treatment in a group of patients with chronic inflammatory demyelinating polyradiculoneuropathy(CIDP), who requires continues treatment of IVIG at regular intervals of 3-10 weeks: 1. During continues treatment of IVIG at regular intervals of 3-10 weeks. 2. During pause in treatment. Hypothesis: 1. The disease activity in the patients are cyclical correlating to the treatment intervals. 2. Pause in treatment will increase disease activity, which can be quantified with symptom scores, disability scales, and clinical test. Primary effect parameter is muscle strength quantified by isokinetic dynamometry. Added to the protocol there is an immunological study of inflammatory markers in blood samples of patients under treatment pause.

NCT ID: NCT00220740 Completed - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

ICE
Start date: April 2004
Phase: Phase 3
Study type: Interventional

The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects. Eight courses of treatment with either placebo or IGIV-C will occur every 3 weeks. Neurological function will be measured by Inflammatory Neuropathy Cause and Treatment (INCAT) scores. Patients who deteriorate or show no improvement between day 16 and month 6 will receive the alternate study drug for an additional 6 months.

NCT ID: NCT00099489 Completed - Clinical trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and through Visit 9 (Week 32, End of Study).

NCT ID: NCT00004939 Completed - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

Start date: August 1996
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Assess the efficacy of 3,4-diaminopyridine in patients with stable chronic demyelinating polyneuropathy.

NCT ID: NCT00004772 Completed - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy

Start date: September 1992
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Compare the response of previously untreated patients with chronic inflammatory demyelinating polyneuropathy to intravenous immune globulin vs. placebo.

NCT ID: NCT00004286 Completed - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy

Start date: February 1996
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Compare and evaluate the response to treatment with intravenous human immune globulin (IVIG) or placebo in previously untreated patients with chronic inflammatory demyelinating polyneuropathy.